Question 1

What is Abbott Laboratories's P/S ratio?

Accepted Answer

Abbott Laboratories (ABT) P/S ratio is 3.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Abbott Laboratories?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Abbott Laboratories specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Abbott Laboratories's P/S ratio high or low?

Accepted Answer

Abbott Laboratories's P/S ratio of 3.8× is below its own 5-year average of 4.6× and above the sector median of 3.4×. That places the current reading at the 5th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Abbott Laboratories's historical P/S ratio range?

Accepted Answer

In the available daily series, Abbott Laboratories (ABT) P/S ratio has ranged from a low of 1.0× in 2011 to a high of 6.0× in 2020. The 5-year average is 4.6× and the 5-year median is 4.7×.

Question 7

What was Abbott Laboratories's P/S ratio in 2025?

Accepted Answer

Abbott Laboratories (ABT) P/S ratio at the end of 2025 was 4.9×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Abbott Laboratories's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$219B	$44.3B	4.9×	+0.3×	Dec 31, 2025
2024	$196B	$42B	4.7×	-0.1×	Dec 31, 2024
2023	$191B	$40.1B	4.8×	+0.4×	Dec 31, 2023
2022	$191B	$43.7B	4.4×	-1.4×	Dec 31, 2022
2021	$248B	$43.1B	5.8×	+0.2×	Dec 31, 2021
2020	$194B	$34.6B	5.6×	+0.8×	Dec 31, 2020
2019	$153B	$31.9B	4.8×	+0.6×	Dec 31, 2019
2018	$127B	$30.6B	4.2×	+0.5×	Dec 31, 2018
2017	$99.5B	$27.4B	3.6×	+0.9×	Dec 31, 2017
2016	$56.6B	$20.9B	2.7×	-0.5×	Dec 31, 2016
2015	$66.1B	$20.4B	3.2×	+0.0×	Dec 31, 2015
2014	$67.9B	$21.3B	3.2×	+0.5×	Dec 31, 2014
2013	$59.3B	$21.8B	2.7×	+1.5×	Dec 31, 2013
2012	$48.9B	$39.9B	1.2×	+0.1×	Dec 31, 2012
2011	$42.3B	$38.9B	1.1×	+0.1×	Dec 31, 2011
2010	$35.6B	$35.2B	1.0×	-0.3×	Dec 31, 2010
2009	$39.9B	$30.8B	1.3×	-0.0×	Dec 31, 2009
2008	$39.5B	$29.5B	1.3×	-0.3×	Dec 31, 2008
2007	$41.5B	$25.3B	1.6×	+0.0×	Dec 31, 2007
2006	$35.9B	$22.5B	1.6×	+0.3×	Dec 31, 2006
2005	$28.9B	$22.3B	1.3×	-0.4×	Dec 31, 2005
2004	$34.7B	$20.3B	1.7×	+0.1×	Dec 31, 2004
2003	$32.7B	$19.7B	1.7×	+0.1×	Dec 31, 2003
2002	$28.1B	$17.7B	1.6×	—	Dec 31, 2002


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
UnitedHealth Group (UNH)	0.8×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
Elevance Health (ELV)	0.4×
Teladoc Health (TDOC)	0.4×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Abbott Laboratories (ABT) 2002-2026

P/S Ratio daily chart for Abbott Laboratories (ABT)

Historical P/S Ratio for Abbott Laboratories (ABT) from 2002 to 2025

About P/S Ratio at Abbott Laboratories (ABT)

Abbott Laboratories P/S Ratio by Year

Abbott Laboratories P/S Ratio 2025: 4.9×

Abbott Laboratories P/S Ratio 2024: 4.7×

Abbott Laboratories P/S Ratio 2023: 4.8×

Abbott Laboratories P/S Ratio 2022: 4.4×

Abbott Laboratories P/S Ratio 2021: 5.8×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Abbott Laboratories (ABT) Key Financials